Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of a Second Treatment Session of RZL-012 Into Submental Fat in Subjects Seeking Further Improvement

NCT05763160 is registered in ClinicalTrials.gov with Raziel Therapeutics Ltd. as lead sponsor.

NCT NCT05763160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05763160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of a Second Treatment Session of RZL-012 Into Submental Fat in Subjects Seeking Further Improvement
Lead sponsor
Raziel Therapeutics Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2023
Completion date
October 20, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

submental fat